Recruitment Status

Not yet recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:33 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3258

Shown on this page

Current sort

Stored official records

Open in full search

Conditions: Inpatient Experience Survey Administration, Inpatient Experience Survey Response, Inpatient Pediatric Care, Inpatient Pediatric Engagement and Shared Decision-Making
Interventions: Anonymous Safety Reporting with Impact Website, Identified Safety Reporting, Safety Reporting Integration Toolkit, Text Plus In-Person Enrollment Strategy, Text-Only Enrollment Strategy; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 21,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Los Angeles, California • Oakland, California • Sacramento, California + 5 more

Conditions: Clear Cell Renal Cell Cancer (ccRCC), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), ccRCC
Interventions: 177Lu-TLX250; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Duarte, California • San Diego, California • Miami, Florida + 5 more

Conditions: Adenotonsillectomy, Postoperative Pain
Interventions: Acetaminophen, Celecoxib, Dexamethasone; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 2 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Self-Titration; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Behavioral Intervention, Fitness Tracker, Physical Activity, Primary Care
Interventions: Physical Activity Counseling Tool (PACT); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Anxiety, Depression, Drug Use, Family Relationships, LGBTQ, Minority Stress, Racial Disparities, Sexual Risk Reduction, Teen Dating Violence
Interventions: Adapted Lakota Family Acceptance Program; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Pine Ridge, South Dakota • Rapid City, South Dakota

Conditions: HIV Infections
Interventions: SEPA+PrEP Women; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Diabetes, Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions: PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab; Device · Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Systemic Sclerosis, Systemic Sclerosis (SSc), Systemic Sclerosis (Scleroderma), Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement
Interventions: C-CAR168; Biological
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Gilbert, Arizona

Conditions: Consciousness, Level Altered
Interventions: Functional Magnetic Resonance Imaging (fMRI), Low-intensity focused ultrasound pulsation (LIFUP), Magnetic Resonance Spectroscopy, Multi-modal glymphatic function MRI; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Disordered Eating Behaviors, Weight Management
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Autoimmune, MS, MS (Multiple Sclerosis), Multiple Sclerosis, Neuro-Degenerative Disease, Neuro-Degenerative Diseases, Primary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progress Multiple Sclerosis (SPMS)
Interventions: C-CAR168; Drug
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Gilbert, Arizona • La Jolla, California

Not yet recruiting clinical trials

Filter and sort this status page

Stored official records

FIQS Dissemination and Implementation

Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC

Preoperative Celecoxib and Acetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric Adenotonsillectomy

Antihypertensive Self-titration in US Primary Care

Guided Physical Activity Counseling: A Pilot Study

Lakota Family Acceptance Project Pilot RCT

SEPA+PrEP-Women Pilot Trial for HIV Prevention Among Women at Risk for HIV

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy

Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation

GLP-1 Impacts on Weight Management

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy